Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice buys into the close,,, Couple more days left in 2023......
Bring on 2024
Level 2 looks very thin on the ask.. January's update, possibly next week may give us the timeline we've been waiting for. You can never predict when news will be released, (Like the unexpected BDD news)
2024 less than a week away . Very much looking forward to the next quarterly update .
Any response produces more FUD. If you want new investors to keep reading FUD , then keep responding. We’re at a very important time in this companies history and that certain poster knows what’s coming which is why he’s here .
New investors will figure out who is credible pretty fast. Ignore
NEWS -- Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation
[Suppressed Image]
Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program.
Dr. Mike Korenko stated “We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data submissions. The FDA did a very thorough review. The analysis in our Risk Management Report concluded that RadioGel™ is intrinsically safe and our animal therapy data verified its effectiveness. We are currently working closely with Mayo Clinic for our initial indication for use of Radiogel for delivering “therapeutic radiation to solid metastatic tumors in lymph nodes associated with papillary thyroid cancer, accessible by percutaneous direct needle injection, in patients who are not surgical candidates or have declined surgery, had non-radioiodine avid disease and had limited burden regional nodal disease.” The Breakthrough Device classification will enhance the schedule priority for our upcoming IDE submission seeking authorization to begin human clinical trials.
The FDA’s Breakthrough Devices program facilitates accelerated development and expedites the review of breakthrough technologies to help patients potentially gain timely access to technologies that can provide more effective treatment options.
Contact for journalists:
Mike Korenko
Email: mailto://MKorenko@RadioGel.com
Time to ignore the nonsense FUD posted on the daily.
Only one person here believes the BDD wasn’t granted by the FDA
The Breakthrough Device classification will enhance the schedule priority for our upcoming IDE submission seeking authorization to begin human clinical trials.
The FDA’s Breakthrough Devices program facilitates accelerated development and expedites the review of breakthrough technologies to help patients potentially gain timely access to technologies that can provide more effective treatment options.
No it wasn’t answered , but that’s expected from someone posting FUD and bashing the CEO on a daily basis .
crickets
BDD granted,,,,,The Breakthrough Device classification will enhance the schedule priority for our upcoming IDE submission seeking authorization to begin human clinical trials.
The FDA’s Breakthrough Devices program facilitates accelerated development and expedites the review of breakthrough technologies to help patients potentially gain timely access to technologies that can provide more effective treatment options.
Simple yes or no question.
Do you believe the company received the BDD from the FDA?
The company reported they did.
And no,, it wasn't asked and answered.
Just answer it.
I'll respond directly to you one time with a question,
Do you believe the company received a BDD from the FDA?
If you don't answer, you're the fraud everyone thinks you are.
Imagine a so called investor SC 8 not believing a word coming from the company or it’s CEO yet remains invested in the company .
Makes no sense
New investors will catch on fast
Old investors already ignore .
Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program.
Dr. Mike Korenko stated “We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data submissions. The FDA did a very thorough review. The analysis in our Risk Management Report concluded that RadioGel™ is intrinsically safe and our animal therapy data verified its effectiveness. We are currently working closely with Mayo Clinic for our initial indication for use of Radiogel for delivering “therapeutic radiation to solid metastatic tumors in lymph nodes associated with papillary thyroid cancer, accessible by percutaneous direct needle injection, in patients who are not surgical candidates or have declined surgery, had non-radioiodine avid disease and had limited burden regional nodal disease.” The Breakthrough Device classification will enhance the schedule priority for our upcoming IDE submission seeking authorization to begin human clinical trials.
The FDA’s Breakthrough Devices program facilitates accelerated development and expedites the review of breakthrough technologies to help patients potentially gain timely access to technologies that can provide more effective treatment options.
Michael K. Korenko, Sc.D.
President • CEO Vivos, Inc.
Mike Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defence.
He currently is the author of 28 patents and has received many awards, including the National Energy Resources Organization Research and Development Award, the U.S. Steelworkers Award for Excellence in Promoting Safety, and the Westinghouse Total Quality Award for Performance Manager of the Year.
Dr. Korenko served as Vice-President of Westinghouse Hanford, Executive Vice President of Closure at Rocky Flats and Chief Operating Officer for Curtiss-Wright Electro-Mechanical Division producer of the nuclear components for all the United States submarines and aircraft carriers and for commercial nuclear power reactors.
He is currently CEO and President of Vivos Inc. developing yttrium-90 brachytherapy for animals and humans.
Loading up before the next quarterly update , which may be the one we’ve been looking for .
Way undervalued considering they got the BDD, and the upcoming IDE imo .
Starts at 36min and 5 sec,,, Thanks Paulness
The right CEO for the job.
Michael K. Korenko, Sc.D.
President • CEO Vivos, Inc.
Mike Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defence.
He currently is the author of 28 patents and has received many awards, including the National Energy Resources Organization Research and Development Award, the U.S. Steelworkers Award for Excellence in Promoting Safety, and the Westinghouse Total Quality Award for Performance Manager of the Year.
Dr. Korenko served as Vice-President of Westinghouse Hanford, Executive Vice President of Closure at Rocky Flats and Chief Operating Officer for Curtiss-Wright Electro-Mechanical Division producer of the nuclear components for all the United States submarines and aircraft carriers and for commercial nuclear power reactors.
He is currently CEO and President of Vivos Inc. developing yttrium-90 brachytherapy for animals and humans.
Michael K. Korenko, Sc.D.
President • CEO Vivos, Inc.
Mike Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defence.
He currently is the author of 28 patents and has received many awards, including the National Energy Resources Organization Research and Development Award, the U.S. Steelworkers Award for Excellence in Promoting Safety, and the Westinghouse Total Quality Award for Performance Manager of the Year.
Dr. Korenko served as Vice-President of Westinghouse Hanford, Executive Vice President of Closure at Rocky Flats and Chief Operating Officer for Curtiss-Wright Electro-Mechanical Division producer of the nuclear components for all the United States submarines and aircraft carriers and for commercial nuclear power reactors.
He is currently CEO and President of Vivos Inc. developing yttrium-90 brachytherapy for animals and humans.
ignore please
How about a concerted effort to ignore the poster who is here to spread FUD?
Lights coming on soon .
To new investors . It’s obvious that there is one poster on this board who’s here to spread FUD on this company and to bash it’s CEO , Dr Korenko. Most have him on ignore .
Exciting times for RDGL and it’s investors with the recent BDD approval and the upcoming IDE submission ( probably in Q1 2024)
Do your own DD and ignore the noise .
Dr Korenko's successes just kills the disgruntled ex employee. I'm sure the 50% increase in share price didn't feel too good either.
ouch.
The guys never leaving . Nothing to sell or liquidate .
Yeah. Bye. Glad you were able to sell
That’s too bad. I thought you were gone when you got your money back. Don’t be so greedy!
Congratulations to $RDGL and Dr. Mike Korenko on their fantastic FDA news today. Perseverance will pay off here and I expect that RadioGel will soon be approved for human trials.
— George Sharp - Advocate for truth in the OTC (@GeorgeASharp) December 20, 2023
RDGL - Radiogel(TM) Precision Radionuclide Therapy(TM)... (https://t.co/1TY3c6cppZ)
IDE coming soon !,,,,BDD granted !!!! The 3 tenors will be moving their concert elsewhere,,, SOON.
This should help fill the offering,,,
You're such a clown. You've been bashing "money wasting Isopet "for years. Maybe now you understand the importance.
Why don't you pack up and leave for good.
LOL,,,The three tenors are scrambling,,,,, they just got hit with a bombshell...
You clowns should start packing and looking for your new gig,,,
BDD granted !!!!!!!!!!! Huge news!!!!!!!!!
I love how the “free shares” investor is ignored by true investors . Big reason is lack of credibility .
FUD being spread on the daily .
He’ll be gone SOON.
Michael K. Korenko, Sc.D.
President • CEO Vivos, Inc.
Mike Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defence.
He currently is the author of 28 patents and has received many awards, including the National Energy Resources Organization Research and Development Award, the U.S. Steelworkers Award for Excellence in Promoting Safety, and the Westinghouse Total Quality Award for Performance Manager of the Year.
Dr. Korenko served as Vice-President of Westinghouse Hanford, Executive Vice President of Closure at Rocky Flats and Chief Operating Officer for Curtiss-Wright Electro-Mechanical Division producer of the nuclear components for all the United States submarines and aircraft carriers and for commercial nuclear power reactors.
He is currently CEO and President of Vivos Inc. developing yttrium-90 brachytherapy for animals and humans.
The guy making promises the share price will be lower says he can’t make any promises.
Michael K. Korenko, Sc.D.
President • CEO Vivos, Inc.
Mike Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defence.
He currently is the author of 28 patents and has received many awards, including the National Energy Resources Organization Research and Development Award, the U.S. Steelworkers Award for Excellence in Promoting Safety, and the Westinghouse Total Quality Award for Performance Manager of the Year.
Dr. Korenko served as Vice-President of Westinghouse Hanford, Executive Vice President of Closure at Rocky Flats and Chief Operating Officer for Curtiss-Wright Electro-Mechanical Division producer of the nuclear components for all the United States submarines and aircraft carriers and for commercial nuclear power reactors.
He is currently CEO and President of Vivos Inc. developing yttrium-90 brachytherapy for animals and humans.
There's only one delusional poster skating around this message board and they know who they are.
These up days seem to increase their post volumes. I wonder why?